IDEXX Laboratories will enhance its Cancer Dx Panel in North America by mid-2026 to include mast cell tumor detection in dogs, complementing its existing lymphoma test used by over 5,500 veterinary practices. This addition addresses over one-third of canine cancer cases and leverages the same blood-based assay, requiring no new specimen types or workflow changes. Turnaround times remain rapid, with results delivered in 2–3 days in the U.S. and 2–4 days in Canada, enabling routine screening of at-risk dogs (≥7 years or high-risk breeds ≥4 years) during wellness visits and targeted testing when tumors are suspected.

In late Q4 2025, IDEXX began deploying its inVue Dx Cellular Analyzer with slide-free fine needle aspiration (FNA) cytology for mast cell tumor evaluation. The analyzer lets veterinarians perform mass sampling, cell identification and quantification in-clinic, with immediate visual results for pet owners. Expert review by IDEXX pathologists is available without manual slide preparation. This platform is designed to expand beyond mast cell tumors over time, streamlining cytology workflows while maintaining high sensitivity and specificity standards.

IDEXX has introduced its ImageVue DR50 Plus, offering high-definition radiography at up to 25% lower radiation dose versus its prior DR50 system and up to 60% less than competing veterinary solutions. The system’s advanced image optimization and irradiated side sampling technologies reduce retakes and improve staff safety—critical in clinics where an estimated 75% of technicians are women of childbearing age. The new 17”×17” detector option expands patient coverage, and seamless integration with IDEXX Web PACS, Telemedicine Consultants (160+ specialists) and ezyVet practice management provides an end-to-end imaging workflow.

These innovations reinforce IDEXX’s position as a leader in veterinary diagnostics, supporting longer-term revenue growth through recurring reference lab tests and capital equipment sales. The Cancer Dx Panel expansion leverages existing lab infrastructure, while the inVue Dx and ImageVue DR50 Plus systems drive equipment and service adoption in clinics. With over 11,000 employees serving 175+ countries and membership in the S&P 500, IDEXX’s strategic investment in oncology and imaging platforms bolsters its competitive moat and aligns with rising demand for early cancer detection and low-dose diagnostic solutions.